csbr

complimenti ho letto il 3D sei un grande ::bow::bow::bow::riesci a trovare in questa merd di mercato pepite d'oro...quando ci vuole ci vuole..:clap::clap:

si trova sempre...
qualcosa di interessante....OK!OK!OK!OK!

O/S 1 settembre 2013
66M
Finding the Right Patients and the Right Drugs.

$ 1,15 2,853 OTO 11/04
$ 1,15 5,000 OTO 11/04
$ 1,15 1,000 OTO 11/04
$ 1,14 1,600 OTO 11/04
$ 1,13 3,000 OTO 11/04
$ 1,12 300 OTO 11/04
$ 1,12 100 OTO 11/04
$ 1,15 400 OTO 11/04
$ 1,15 3,846 OTO 11/04
$ 1,16 1,700 OTO 11/04
$ 1,18 500 OTO 11/04
$ 1,19 1,000 OTO 11/04
$ 1,20 100 OTO 11/04
$ 1,20 100 OTO 11/04
$ 1,20 100 OTO 11/04
$ 1,20 2,000 OTO 11/04
$ 1,20 9,000 OTO 11/04
$ 1,21 23,450 OTO 11/04
$ 1,21 250 OTO 11/04
 

Allegati

  • csbr.png
    csbr.png
    19,6 KB · Visite: 104
HACKENSACK, N.J., Sept. 13, 2013 (GLOBE NEWSWIRE) -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Recent Highlights:
Quarterly revenue of $3.02 million
Signing of partnership with Teva
Regulatory approval from New York Department of Health
Hiring of two senior executives
Joel Ackerman, Champions Oncology CEO, stated, "The first fiscal quarter of 2014 was a great start for the year. Our financial results were strong in both segments, driven by robust growth and margins. We also had a number of accomplishments that don't show up in the numbers but set the stage for the future."
Revenue was $3.02 million, as compared to $2.1 million for the three months ended July 31, 2012, an increase of 43%. Total operating expenses were $3.8 million, as compared to $3.7 million for the three months ended July 31, 2012.
Champions reported a loss from operations of $0.77 million as compared to a loss from operations of $1.6 million for the three months ended July 31, 2012. Excluding stock-based compensation of $0.55 million and $0.74 million for the three months ended July 31, 2013 and 2012, Champions recognized a loss from operations of $0.2 million and a loss from operations of $0.9 million for three months ended July 31, 2013 and 2012, respectively.
Operating Results
Personalized Oncology Solutions (POS):
The number of implants during the quarter was 65, an increase of 141% over the same period last year. The increase in implants is the result of growing visibility with patients and physicians, the reduction in patient costs per implant and expanding our international operations. The number of patients for whom studies were completed was 22 for the quarter, an increase of 69% over the same period last year. The increase in patient studies is the result of higher implant volumes in the recent quarters which lead to studies in subsequent quarters. POS revenues were $0.6 million and $0.9 million for the three months ended July 31, 2013 and 2012, respectively, a decrease of $0.3 million or 32.2%. The decrease is due to the decrease in non-core physician panel revenue of $0.3 million. This is due to the strategic decision to focus on our core products and services.
POS cost of sales was $0.79 million and $0.77 million for the three months ended July 31, 2013 and 2012, respectively, an increase of $0.02 million, or 2.7%. For the three months ended July 31, 2013 and 2012, gross margins for POS were -27.5% and 16%, respectively. The gross margin in this business segment fluctuates based on a number of factors including business mix, pricing and volumes.
Translational Oncology Solutions (TOS):
TOS revenues were $2.39 million and $1.18 million for the three months ended July 31, 2013 and 2012, respectively, an increase of $1.21 million, or 102%.
TOS cost of sales was $0.88 million and $0.7 million for the three months ended July 31, 2013 and 2012, respectively, an increase of $0.2 million, or 26%. For the three months ended July 31, 2013 and 2012, gross margins for TOS were 63% and 41%. The increase in gross margin is due to the leveraging of the fixed component of cost of sales over a higher revenue amount and the absorption of certain costs associated with this quarter's revenue in previous quarters.
Research and development expense was $0.4 million for three months ended July 31, 2013 and 2012, respectively. Sales and marketing expense was $0.6 million and $0.7 million for the three months ended July 31, 2013 and 2012, respectively, a decrease of $0.1 million, or 9.4%. General and administrative expense was $1.07 million and $1.14 million for the three months ended July 31, 2013 and 2012, respectively, a decrease of $0.07 million, or 5.9% due to the decrease in stock compensation expense.
Conference Call Information:
The Company will host a conference call on Friday, September 13, 2013, at 8:30 a.m. ET to discuss its first quarter financial results. To access the conference call, domestic participants should dial 800-875-3456, Canadian participants should dial 800-648-0973, and international participants should dial 302-607-2001. The participant passcode is "Champions Oncology."
Full details of the Company's financial results will be available in the Company's Form 10-K at Finding the Right Patients and the Right Drugs..
* Non-GAAP Financial Information
See the attached Reconciliation of GAAP loss from operations to non-GAAP loss from operations for an explanation of the amounts excluded to arrive at non-GAAP loss from operations and related non-GAAP loss from operations per share amounts for the three months ended July 31, 2013 and 2012. Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis. Certain unusual or non-recurring items that management does not believe affect the Company's basic operations do not meet the GAAP definition of unusual or non-recurring items. Non-GAAP loss from operations and non-GAAP loss per share are not, and should not be viewed as a substitute for similar GAAP items. We define non-GAAP dilutive loss per share amounts as non-GAAP loss from operations divided by the weighted average number of diluted shares outstanding. Our definition of non-GAAP loss from operations and non-GAAP diluted loss per share may differ from similarly named measures used by others.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through its Personalized Oncology Solutions
 
devono fare un split
x andare
nyse
o
nasdaq

PROPOSAL NO. 5

GRANT THE BOARD OF DIRECTORS DISCRETIONARY AUTHORITY TO AMEND THE COMPANY’S CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE COMPANY’S COMMON STOCK

General
On August 15, 2013, our Board of Directors unanimously approved and recommended that our stockholders (a) approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse split of our common stock at a ratio ranging from one-for-three to one-for-ten, and (b) grant authority to the Board of Directors (i) to decide whether to effect the reverse split, and (ii) if the Board decides to effect the reverse split, then to determine, in the discretion of the Board of Directors, which specific ratio shall be included in the amendment to effect the reverse split.

The form of the amendment to our Amended and Restated Certificate of Incorporation to effect the reverse split is attached to this Proxy Statement as Appendix A. The following discussion is qualified in its entirety by the full text of the amendment, which is hereby incorporated by reference.

Pursuant to the reverse split, as appropriate and depending upon market and other conditions, at the discretion of the Board of Directors, between each three and ten of the outstanding shares of our common stock on the date of the reverse split will be automatically converted into one share of our common stock. The reverse split will not alter the number of shares of common stock authorized for issuance, but will simply reduce the number of shares of common stock issued and outstanding. The reverse split will be effected only upon a determination by the Board of Directors that the reverse split is in the best interest of the Company and its stockholders, and thereupon the Board of Directors will select, at its discretion, the ratio of the reverse split, which will between one-for-three and one-for-ten.

By approving this proposal, stockholders will approve the amendment to our Amended and Restated Certificate of Incorporation reflecting one of the foregoing ratios and authorize our Board of Directors to decide whether to effect the reverse split and, if the Board decides to effect the reverse split, to select which split ratio is appropriate. If the amendment to our Amended and Restated Certificate of Incorporation is approved and the Board of Directors elects to file the amendment to our Amended and Restated Certificate of Incorporation and effect the reverse split, then the Board of Directors will select one of the ratios and we will insert the selected ratio into the amendment and file the amendment to the Amended and Restated Certificate of Incorporation with the New York Department of State. The reverse split will become effective upon the filing of the amendment to our Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Effective Date”). The Board believes that stockholder approval of granting the Board this discretion over whether to effect the reverse split and, if the Board decides to effect the reverse split, which ratio to select, rather than stockholder approval of a mandatory reverse split and/or a specified ratio, provides the Board with maximum flexibility to react to then-current market conditions and, therefore, is in the best interests of the Company and its stockholders.

Purpose of the Proposed Reverse Split

Potential for listing on NASDAQ or the New York Stock Exchange through increase in bid or closing price

The Board of Directors believes that the reverse split is desirable because it will assist the Company in meeting the requirements for initial listing on NASDAQ or the New York Stock Exchange (NYSE) by helping to raise the bid or closing price for our common stock. Currently, our common stock is quoted on the Over-the-Counter Bulletin Board (OTCBB), which is not a national securities exchange. One of the key requirements for initial listing on NASDAQ or NYSE is that our common stock must have met certain minimum bid or closing prices, generally ranging between $3 per share and $5 per share, depending on the exchange. Our common stock currently does not meet these minimum bid or closing price requirements.

As a result of our common stock being listed on NASDAQ or NYSE, the liquidity of our common stock and coverage of our company by security analysts and media could be increased, which could result in higher prices for our common stock than might otherwise prevail, lowered spreads between the bid and asked prices for our common stock and lowered transaction costs inherent in trading such shares. Additionally, certain investors will only purchase securities that are listed on a national securities exchange, and such listing could thus increase our ability to raise funds through the issuance of our common stock or other securities convertible into our common stock. Moreover, listing our shares on a national securities exchange is a requirement for using Form S-3, a short form registration statement, for registering the issuance of our shares or the resale of existing shares. The ability to use Form S-3 may speed up the time it takes for us to raise funds through the issuance of our shares and increase our ability to do so.
 
questo è molto interessante$$$$$$$$$$$$$

TEVA) recently entered into an agreement with Champions Oncology Inc. (CSBR) for the development of advanced technology solutions and services so that the evaluation and use of oncology drugs can be personalized.
Champions Oncology’s TumorGraft technology platform will be used to improve and speed up the development of several of Teva's oncology compounds.
Under the partnership, the TumorGraft technology platform will be used to identify highly responsive cancer subtypes and their corresponding molecular and biochemical biomarkers of responsiveness to Teva's novel therapeutic agents. The ultimate target is to develop new and personalized therapeutic options for cancer patients.
Champions Oncology is entitled to an upfront payment from Teva as well as milestone payments. Teva will pay royalties as well.
Teva has signed another oncology deal, this one with the technology development arm of Cancer Research UK’s - Cancer Research Technology Ltd. (CRT). The multi-project alliance is aimed at the research and development of first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.
We note that Teva has been working on strengthening its oncology portfolio. The lead product in the company’s oncology product portfolio is Treanda. Treanda, which became a part of Teva’s portfolio following its acquisition of Cephalon, posted sales of $608 million in 2012.
Teva currently carries a Zacks Rank #3 (Hold). The company is going through a tough transition period given fewer large generic opportunities, potential new competition for branded products (especially Copaxone) and a higher cost base.
However, we are encouraged by Teva’s plans to improve its position. Teva said that it intends to accelerate growth platforms, protect and expand core franchises, expand its global presence, pursue strategic deals and reduce the cost base. We expect investor focus to remain on the execution of the company’s new strategy.
 
questo è molto interessante$$$$$$$$$$$$$

TEVA) recently entered into an agreement with Champions Oncology Inc. (CSBR) for the development of advanced technology solutions and services so that the evaluation and use of oncology drugs can be personalized.
Champions Oncology’s TumorGraft technology platform will be used to improve and speed up the development of several of Teva's oncology compounds.
Under the partnership, the TumorGraft technology platform will be used to identify highly responsive cancer subtypes and their corresponding molecular and biochemical biomarkers of responsiveness to Teva's novel therapeutic agents. The ultimate target is to develop new and personalized therapeutic options for cancer patients.
Champions Oncology is entitled to an upfront payment from Teva as well as milestone payments. Teva will pay royalties as well.
Teva has signed another oncology deal, this one with the technology development arm of Cancer Research UK’s - Cancer Research Technology Ltd. (CRT). The multi-project alliance is aimed at the research and development of first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.
We note that Teva has been working on strengthening its oncology portfolio. The lead product in the company’s oncology product portfolio is Treanda. Treanda, which became a part of Teva’s portfolio following its acquisition of Cephalon, posted sales of $608 million in 2012.
Teva currently carries a Zacks Rank #3 (Hold). The company is going through a tough transition period given fewer large generic opportunities, potential new competition for branded products (especially Copaxone) and a higher cost base.
However, we are encouraged by Teva’s plans to improve its position. Teva said that it intends to accelerate growth platforms, protect and expand core franchises, expand its global presence, pursue strategic deals and reduce the cost base. We expect investor focus to remain on the execution of the company’s new strategy.

TEVA NYSE
HA MESSO LE MANI SU CSBR
PRIMA DEVE PASSARE
AL MERCATO SUPERIORE
E POI SI IMPADRONISCE
DEL PRODOTTO DI PUNTA DEL NOSTRO TITOLO

PS: è UN FILM GIA' VISTO
IN PRIMA SERATA:D:D:D:D:D:D:D

non mi spaventa r/s
è fatto per andare avanti:yes::yes::yes::yes::yes:
 
io compro a mani basse
adesso 1.14
 
siamo in due amico.......
 
....

here's your chance
 

Allegati

  • csbr.png
    csbr.png
    19,6 KB · Visite: 76
MM con i contro c.o.g.l.i.o.n.i
in bid

webd
 
siamo quasi pronti per il mercato
superiore,,,,,
up
 

Allegati

  • csbr.png
    csbr.png
    19,5 KB · Visite: 46
lo so
tesoro
non avevo soldi
tutto legato:angry:

:grrr:

baci


oggi posso fare......
 
ho investito
4miladollari$$$$$$$$

1.29

2014 ricco???????
:yes::angry::censored::D
 
Indietro